Fatigue is one of the most frequent complaints among breast cancer survivors. However, mechanisms underlying persisting fatigue after end of treatment are poorly understood. To explore whether biological processes underlying persistent fatigue can affect gene expression of blood cells, genome-wide expression analyses were performed on whole blood samples from breast cancer survivors classified as chronic fatigued 2-6 years after diagnosis. Non-fatigued survivors served as controls. Several gene sets involved in plasma-and B-cell pathways differed between the chronic fatigued and the non-fatigued, suggesting that a dysregulation in these pathways is associated with chronic fatigue and that a B-cell-mediated inflammatory process might underlie fatigue. The chronic fatigued also had a higher level of leucocytes, lymphocytes and neutrophiles compared with the non-fatigued, thus further indicating that an activation of the immune system plays a role in the biology of chronic fatigue in breast cancer survivors.
Introduction
Advances in detection and treatment of breast cancer have lead to an increasing number of cancer survivors, and the 5-year relative survival for Norwegian women with breast cancer is now 87.5%. 1 In consequence, late effects and optimal quality of life have become new important end points in cancer care, requiring separate research efforts to minimize the long-term negative impact of the cancer and its treatment. Fatigue has been reported to be one of the most distressing and common late effects experienced by breast cancer survivors, affecting as many as 30%. [2] [3] [4] [5] [6] Fatigue negatively affects work, sleep, social relationships and daily life and leads to a reduction in overall quality of life. 2, 5, 7 Despite the high prevalence of fatigue and fatigue's negative impacts, the etiology and mechanisms underlying the symptom have yet to be determined. Further, no specific treatment is available, and at present, treatment is based on more general principles such as aerobic training and lifestyle management. Earlier studies on possible mechanisms have found no consistent association between fatigue and stage of disease, extent of treatment, time since treatment completion, type of surgery or use of tamoxifen. 5, 7, 8 Some studies have investigated the role of the immune system and, in particular, the role of cytokines in relation to fatigue in breast cancer survivors. [9] [10] [11] [12] [13] [14] [15] Fatigued breast cancer survivors have been shown to have significantly higher levels of proinflammatory cytokines and circulating T lymphocytes compared with non-fatigued survivors. 9, 10, 15 Bower et al. 11, 12 showed that fatigued breast cancer survivors had an altered diurnal cortisol rhythm, and, compared to non-fatigued survivors, a blunted cortisol response to experimental stressors. These findings may suggest dysregulation in the hypothalamic-pituitary-adrenal axis functioning. However, others have found no difference in cortisol levels between fatigued breast cancer survivors and controls, thus contradicting the findings of altered hypothalamicpituitary-adrenal axis functioning. 16 Thus, the exact mechanisms leading to persistent fatigue in breast cancer survivors are still unknown.
This study was designed to explore the biological processes underlying fatigue by studying blood gene expression of the entire transcriptome in chronic fatigued breast cancer survivors relative to non-fatigued breast cancer survivors. By this approach we do not rely on earlier hypotheses and today's view of the most likely pathways involved, but are instead searching for differences in the total transcriptome in chronic fatigued vs non-fatigued breast cancer survivors to enable an unbiased and unsupervised search for the possible biological mechanisms involved. An understanding of the processes involved can form the basis for new treatments or prophylactic efforts.
Results
All 403 women included in the study (see Figure 1 for overview of sampling) had undergone curatively intended surgery for stage II/III breast cancer followed by radiotherapy, either with standardized field arrangements or based on dose planning on computed tomography images. Most of the patients were treated with chemotherapy and/or hormone therapy (Supplementary Table S1 ). Reliable gene expression data from whole blood was retrieved from 329 of the 403 cases. Analyses of the gene expression data comparing patients classified as chronic (duration 46 months) fatigued in 2004 (n ¼ 85) with patients without chronic fatigue in 2004 (n ¼ 162), regardless of their status in 2007, yielded no significant results by single gene analysis nor by gene sets. To maximize the possible differences within the cohort, the sample set was then divided into subjects having chronic fatigue at both assessments (2004 and 2007) (n ¼ 49) and those not reporting chronic fatigue at any assessment (n ¼ 88). Patients with chronic fatigue at only one of the two assessments were thus excluded, yielding a total of 137 patients. Table 1 shows an overview of the tumor and treatment characteristics of these 137 patients.
Fatigue can be a symptom of a depressive disorder, and fatigue, anxiety and depression are moderately correlated. We therefore explored the distribution of probable depression and anxiety cases as measured by the Hospital Anxiety and Depression Scale (HADS) (see Materials and methods) in the fatigued and the non-fatigued groups by performing a w 2 test with Yates' continuity correction ( Table 2 ). The P-value of 4.581 Â 10 -4 showed that there was a clear difference in the distribution of HADS positive (anxiety (Table 2) . Therefore, in the subsequent data analyses two different groupings of the survivors were employed: grouping A included all chronic fatigued survivors, irrespective of their HADS status, and compared them with the non-fatigued survivors, and grouping B included the chronic fatigued survivors who were also HADS negative and compared them with the non-fatigued survivors ( Table 3 ). The non-fatigued groups are equal in the two analyses.
Blood cell counts
A Welch two-sample t-test was performed on the blood cell counts to look for differences between the fatigued and the non-fatigued survivors of grouping A ( Table 4 ). The results revealed that the levels of leukocytes, lymphocytes and neutrophiles were higher in the fatigued than in the nonfatigued survivors. Still, the number of cells was within the normal range in both groups. No differences in the levels of hemoglobin or eosinophiles were found. A Welch twosample t-test performed on blood cell counts for grouping B showed that the lymphocyte count was higher in the fatigued group compared with the non-fatigued group (mean in the fatigued group ¼ 1.72, mean in the nonfatigued group ¼ 1.49, P-value ¼ 0.036).
Gene expression and fatigue
Global analysis of covariance (GlobalAncova) performed on blood gene expression data comparing the fatigued and the non-fatigued survivors in grouping A and in grouping B yielded non-significant results for both analyses (Table 5 ). GlobalAncova applied on the chronic fatigued in analyses grouping A looking for differences between the HADS positive survivors (n ¼ 20) vs the HADS negative survivors (n ¼ 29), yielded borderline significant results (Table 5) . A single linear analysis applied to both grouping A and grouping B identified only one gene as differentially expressed with a false discovery rate (FDR) below 0.20 in each group (Table 6 ). In the analyses of grouping A PLOD1 (procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1), a gene involved in glycoprotein metabolism was downregulated 
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Hege Landmark-Høyvik et al in the fatigued group, whereas the gene NPCDR1 (nasopharyngeal carcinoma, downregulated 1) was upregulated in the fatigued in grouping B. The results from GlobalAncova and linear analyses suggested that there were no or only one linear association of single gene expression in blood and chronic fatigue in the two groups. We subsequently moved beyond the single-gene approach and performed gene set enrichment analyses (GSEA) on the two groups separately, using pathways from the Molecular Signature Database (MSigDB). GSEA on all pathways from MsigDB on grouping A identified five gene sets as enriched in the fatigued, whereas no gene sets were recognized as enriched for the non-fatigued (Tables 6 and 7 ). The enriched pathways included two gene sets consisting of genes found differentially expressed between multiple myeloma subclasses (gene set 1 and 5, Table 7) , 17, 18 one gene set involved in B-cell lymphoma (gene set 2, Table 7) , 19 a gene set involved in the B-cell lymphocyte immune function (BCR pathway, gene set 3, Table 7 ) and one gene set consisting of genes induced in B cells when exposed to interleukin-4 cytokine (gene set 4, Table 7 ). 20 The analyses of grouping B showed that no pathways were recognized as enriched for the non-fatigued group, but one pathway, nucleotide sugars metabolism, was found enriched in the fatigued group (Tables 6 and 7) .
Leading edge analysis performed on the five identified gene sets in grouping A revealed that 103 genes contributed to the enrichment results (Table 8; Figure 2 ). The genes in the leading edge subsets from each gene set showed very little gene overlap between the five gene sets, only four of the core genes (BLNK, PRKCB1, SLA, CD79B) are shared between two or more leading edge subsets. Several of the core genes identified are involved in B-and T-cell functions, whereas some genes are involved in stress/cytokine response ( Table 9 ). The core genes from all the five gene sets showed low expression in the fatigued compared with the nonfatigued.
By performing GSEA on only these five gene sets on grouping B, one gene set (ZHAN_MULTIPLE_MYELOMA_ SUBCLASSES_DIFF ) was significant (FDR ¼ 0.10). 17 As the blood cells counts showed differences in the number of some blood cell types, we wanted to explore the expression of blood cell type-specific genes further. GSEA was performed on five different gene sets with genes specific for different blood cell types as described by Whitney et al. 21 One gene set specific for reticulocytes (ES score ¼ 0.841, FDR ¼ 0.23) was significantly differentially expressed in the non-fatigued group in grouping A with an FDR below 0.25, whereas none of the gene sets were significant in grouping B. The core genes in the reticulocyte gene set that contributed to the enrichment results in grouping A are shown on top in Figure 2 . Among the core genes is a gene encoding erythrocyte membrane protein (EPB42), genes involved in the suppression of apoptosis in erythropoietins during erythropoisesis (BCL2L1 and BNIP3L) 22 and several hemoglobin genes (HBD, HBG1, HBG2, HBQ1 and HBZ).
Discussion
Fatigue is a frequent complaint among breast cancer survivors and has a major negative impact on their daily lives, but the etiology of fatigue is still poorly understood. In this study, gene expression analyses were performed on whole blood samples from breast cancer survivors with and without chronic fatigue to look for different expression patterns that might shed light on the biology of fatigue. Blood cells can be viewed as surveyors of the body's homeostasis, continuously searching for signs of infection and mounting a rapid defense in cases of threats. The expression of blood cells in chronic fatigued breast cancer survivors compared with non-fatigued survivors may therefore provide valuable information about pathways underlying fatigue.
The fatigue questionnaire (FQ) questionnaire was used to measure fatigue and classify the survivors as fatigued or nonfatigued, and the fatigue groups in this study consisted of survivors who were classified as either fatigued or nonfatigued at two consecutive time points. By dichotomizing into fatigued and non-fatigued, theoretically one might loose variance and thereby reduce the possibility to identify predictors of fatigue. On the other hand, fatigue is common and is observed in relation to many daily stressors. We also used duration of 6 months or longer as a criterion for being fatigued. We thereby excluded those with fatigue of short duration and possibly related to more circumstantial causes. This should theoretically increase the explaining power of our model. The level of anxiety and depression was assessed by the HADS questionnaire. The results from the GlobalAncova on the chronic fatigued with HADS positive status vs the chronic fatigued with a HADS negative status indicated that there are expression differences between the two groups, although borderline significant that suggests that the fatigued survivors might be divided into biologically different subgroups depending on their level of anxiety and depression. This is supported by the fact that the GSEA analyses on grouping A (both HADS positive and negative survivors) and grouping B (only HADS negative survivors) yielded different results. Although the association between fatigue and anxiety and depression is well known, this association cannot offer a full understanding of fatigue in cancer survivors. 2, 4, 16 The relationship between fatigue and depression is also intricate, because depressed mood may arise as a consequence of being fatigued and because fatigue is accepted as a symptom of depressive disorders.
The results from GlobalAncova and linear analysis on grouping A and grouping B indicated that there is no linear CCT4  ABCG1  BLNK  ARPC5  BCL10  CKS1B  ARNTL  BTK  BCL6  BCL11A  CSNK2B  CITED2  CD79A  CD79B  BLNK  DFFA  GAPDH  CD79B  FCER2  BRDG1  EIF2S1  HADHA  ELK1  GNG2  CD1D  EWSR1  IK  GRB2  GSR  CXCR4  EZH2  LIG1  LYN  IL4R  DUS2L  FKBP1A  LOC90925  MAP2K1  KIAA0746  GM2A  FNTA  ME2  MAP3K1  KMO  LAMA5  MTIF2  PDCD4  MAPK14  MAL  LOC650369  PRKDC  PRKCB1  MAPK3  NCOA3  PIK3AP1  PSMD14  RPL14  NFATC1  NFIL3  PNOC  RANBP1  SLA  NFATC3  PPP2CA  PRKCB1  TMEM131  STAT5B  PPP3CC  PPP6C  RNGTT  UBE2V2  TBL3  PRKCB1  RPL5  RYK  UGP2  TLE1  SYK  SAMSN1  ST6GAL1  ZNF274  VAV1  SELL  TLK1  SLA  TLOC1  SMARCA2  XBP1  # core association between single gene expression in blood and fatigue status, because only a single gene was found differentially expressed in the analyses of the two groupings. The GSEA results on all gene sets (n ¼ 1892) from grouping A reported five gene sets as significantly differentially expressed between the chronic fatigued and non-fatigued. All of the five gene sets are concerned with pathways involving plasma or B cells. Three of the gene sets are involved in neoplasia of plasma or B cells, whereas the other two gene sets are involved in B-cell responses. A plasma cell develops from B cells in response to antigen presentation and T-cell activation, and is a fully differentiated lymphocyte in the B-cell lineage. Each plasma cell synthesizes and secretes one type of antibody, which will target and bind to an antigen for destruction. This is an important part of the body's immune system. In multiple myeloma, a plasma cell disorder, cancerous plasma cells build-up in the bone marrow, leaving too little room for the production of normal amounts of red blood cells, white blood cells and platelets. Diffuse large B-cell lymphoma is a disorder of the B cells that forms aggressive nodal or extranodal tumors. Two of the gene sets that were lower expressed in the chronic fatigued than in the non-fatigued in the analyses of grouping A are involved in multiple myeloma and one in diffuse large B-cell lymphoma, suggesting that fatigue might engage some of the same pathways that are deregulated in these types of plasma and B-cell disorders. The B-cell antigen receptor pathway (BCR) that was downregulated in the chronic fatigued is involved in the B cell's recognition of a specific antigen and the B cell's subsequent activation to mature B cells. Stimulation of the BCR receptor can also lead to proliferation or apoptosis depending on the cell environment and the cell's differentiation status. 23 The last gene set that was downregulated in the chronic fatigued compared with the non-fatigued includes genes that are induced in B cells in response to interleukin-4 stimulation. The cytokine interleukin-4 is a survival factor for B-and T-cell lymphocytes and can prevent primary lymphomas from entering apoptosis. 23 These two pathways being expressed differently in the chronic fatigued compared with the non-fatigued lends further support to the hypothesis that a deregulation in the plasma-and B cells might be an underlying etiology of persistent fatigue. The leading edge analysis revealed that only 4 of the 103 core genes were in common between the five gene sets. Thus, these gene sets were not found differentially expressed between the chronic fatigued and non-fatigued because they contained the same genes, but, in fact, the five gene sets contain different genes involved in the same biological processes. Some of the core genes are involved in B-and T-cell processes and several are involved in cytokine and stress responses. Earlier research has suggested that increased proinflammatory cytokine activity and increased cytokine production in response to lipopolysaccharides are associated with chronic fatigue. 9, 13, 15, 24 Our findings support this hypothesis to some extent, because many of the core genes are involved in cytokine and stress responses, and the gene sets identified are part of the immune system. Our results indicate that a B-cell-mediated inflammatory process might underlie fatigue.
The chronic fatigued in the analyses of grouping A had a higher count of leukocytes, lymphocytes and neutrophiles than the non-fatigued. This may indicate an overactive immune system in the fatigued survivors, and supports the findings from our gene expression analyses. In an earlier study, no differences in the absolute number of B cells were found, but the authors reported increased levels of circulating T lymphocytes in fatigued breast cancer survivors. 10 In contrast to our study, the number of B cells was counted, whereas we counted the total number of lymphocytes (consisting of B cells, T cells and natural killer cells), and comparison across the studies cannot, therefore, be performed. Further, Bower et al. did not find any differences in the number of granulocytes between fatigued and nonfatigued survivors. However, in that study, the granulocytes were not differentiated and the fraction of neutrophiles was not reported, as in our study. Possible differences in the number of neutrophiles might therefore have been masked by different number of other granulocytes. The increased fraction of neutrophiles in the chronic fatigued survivors is consistent with the finding in a recent paper on fatigued breast cancer survivors. 16 That study also reported an increased level of total leukocytes in the chronic fatigued survivors, similar to our results. However, the level of lymphocytes did not differ between the chronic fatigued and the non-fatigued, as our results indicate. This might be related to the longer time since end of treatment in our study (2-6 years vs 3 months-2 years). We could not show any difference in hemoglobin levels between the chronic fatigued and the non-fatigued, confirming the results from the study by Alexander et al. 16 This supports that anemia is not involved in fatigue in breast cancer survivors, contrary to what has been proposed in cancer patients undergoing therapy. 25, 26 The GSEA analysis on gene sets for different blood cell types showed that a gene set for reticulocytes had a generally higher expression in the chronic fatigued in grouping A. Several genes coding for hemoglobin were among the core genes, suggesting a possible linkage between fatigue and the hemoglobin synthesis. An information letter, including the informed consent form and a questionnaire package were mailed to 415 eligible survivors. Of these survivors, 315 (76%) answered the questionnaire package and also came to an outpatient clinical examination including blood sampling for DNA and RNA analyses.
In . The chronic fatigued survivors had a sum of dichotomized scores X4 and duration X6 months. The levels of anxiety and depression were measured by the HADS. 29 HADS positivity was assigned for the survivors with a sum score X8 within each scale.
Laboratory methods. White blood cell counts were recorded for all the participants using standard cell counting on CellDyn 3200/Cell-Dyn 4000 from Abbott (Stonefort, IL, USA).
Total RNA for 403 participants were isolated from PAX tubes at AROS Applied Biotechnology (Aarhus, Denmark) by an automated procedure using the column-based technologies from Qiagen Inc. (Hilden, Germany). Samples with concentrations o20 ng ml À1 were excluded (50 samples). The remaining samples were submitted to an Agilent Bioanalyzer (Palo Alto, CA, USA) to validate RNA quality and samples with an RIN value o6 were excluded (22 samples). Samples with concentrations o25 ng ml À1 (51 samples) were upconcentrated using a DNA 120 Speedvac from Thermo Savant (Waltham, MA, USA).
RNA amplification was performed on a total of 331 samples using 300 ng of total RNA, and the Illumina Totalprep RNA Amplification kit (Ambion Inc., Austin, TX, USA). The amplification procedure consists of reverse transcription with a T7 promoter and ArrayScript, followed by second-strand synthesis. In vitro transcription with T7 RNA polymerase using a biotin-NTP mix produced biotinylated cRNA copies of each mRNA in the sample. A total of 329 samples were run on the Illumina Human-6 version 2 expression bead chips (two samples were excluded after amplification because of too low RNA concentration after amplification). Bead Studio from Illumina (San Diego, CA, USA) was used to assess the quality of each array.
Statistical analyses. The data analyses were conducted in R version 2.7.2. (http://cran.r-project.org), and tools from the Bioconductor project (http://www.bioconductor.org) adapted to our needs were used. Preprocessing of the microarray data was performed using the lumiR package. Samples found to be outliers with detection-outlier plots, principal component analyses, coefficient of variation plots and present-count plots were excluded (10 samples). The gene list was filtered to exclude all genes that did not have an expression value in at least 80% of the samples, resulting in 11 942 as the total number of probes. Variance stabilization was performed using variance stabilization transformation (vst) 30 and the data were normalized by quantile normalization. Global analysis of covariance (ANCOVA) 31 on all the available technical variables (e.g array batch, date of extraction, amplification and hybridization) was performed and showed that there was no technical variability in our dataset.
GlobalAncova was used to search for differences in gene expression between the chronic fatigued and the nonfatigued survivors. A single linear analysis was applied to look for differentially expressed genes between the chronic fatigued and the non-fatigued in grouping A and in grouping B, and a FDR test was used to correct for multiple testing. 32 GSEA was used to search for differences in gene sets extracted from the MsigDB between the chronic fatigued and the non-fatigued in grouping A and in grouping B. 33 In an exploratory approach, all curated gene sets (C2 in MsigDB, n ¼ 1892) collected from various sources, such as online pathway databases, publications in PubMed and knowledge of domain experts, were investigated. Leading edge analysis was performed on the GSEA results to further investigate pathways identified through GSEA. Leading edge analysis identifies the leading edge subset, which represents the core genes of a gene set that contribute the most to the enrichment results.
